Muscle Cell News 2.23 July 10, 2017 | |
| |
TOP STORYCNIO Scientists Link New Cancer Treatments to Cardiovascular Alterations Scientists discovered how the Plk1 protein not only regulates tumor growth but also the control of contraction of the arteries and blood pressure. [Press release from the Spanish National Cancer Research Centre (CNIO) discussing online prepublication in Nature Medicine] Press Release | Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)CARDIAC MUSCLE CELLSIt has been shown that interleukin-10 (IL10) suppresses pressure overload (PO)-induced cardiac fibrosis; however, the role of IL10 in inhibition of bone marrow fibroblast progenitor cell (BM-FPC)-mediated cardiac fibrosis is not known. Investigators hypothesized that IL10 inhibits PO-induced homing of BM-FPCs to the heart and their trans-differentiation to myofibroblasts and thus attenuates cardiac fibrosis. [Circulation] Abstract Scientists developed a novel method to deliver stem cells using 3D bioprinted cardiac patches, free of biomaterials. Human induced pluripotent stem cell-derived cardiomyocytes, fibroblasts and endothelial cells were aggregated to create mixed cell spheroids. [Sci Rep] Full Article To push human induced pluripotent stem cell-derived cardiomyocytes towards maturation, researchers recapitulated the intrinsic cardiac properties by electro-mechanical stimulation and explored how these mimetic biophysical cues interplay and influence cell behavior. [Prog Biophys Mol Biol] Abstract SKELETAL MUSCLE CELLSInvestigators identified a long-lived stem cell pool that mediates growth of the zebrafish myotome. Meox1 initiated G2 cell-cycle arrest within muscle stem cells, and disrupting this G2 arrest caused premature lineage commitment and resulted in defects in muscle growth. [Cell Stem Cell] Abstract | Graphical Abstract | Press Release A Defect in Myoblast Fusion Underlies Carey-Fineman-Ziter Syndrome Researchers reported that autosomal recessive mutations in myomaker (MYMK) caused Carey-Fineman-Ziter syndrome in humans by reducing but not eliminating MYMK function. [Nat Commun] Full Article | Press Release Scientists investigated the potential of muscle-derived PW1+/Pax7– interstitial progenitor cells as a source of tissue-specific stem/progenitor cells with stem cell properties and multipotency. [Stem Cell Res Ther] Full Article IGFN1_v1 Is Required for Myoblast Fusion and Differentiation To reveal possible roles for Igfn1, researchers applied non-selective knock-down by shRNAs as well as specific targeting of Igfn1 exon 13 by CRISPR/Cas9 mutagenesis in C2C12 cells. [PLoS One] Full Article SMOOTH MUSCLE CELLSThe authors provided evidence that Ca2+ entry through L-type voltage-dependent Ca2+ channels in vascular smooth muscle can pass to the endothelium through positions aligned with holes in the internal elastic lamina in amounts sufficient to activate endothelial cell Ca2+ signaling. [Sci Signal] Abstract Investigators examined differences in the differentiation of male and female human pluripotent stem cells into smooth muscle progenitor cells, and investigated the effect of 17β-estradiol on the extracellular matrix metabolisms and cell proliferation rates of the smooth muscle progenitor cells. [Stem Cell Res Ther] Full Article | |
| |
REVIEWSCellular Mechanisms Underlying Cardiac Engraftment of Stem Cells Scientists outlined the challenges confronting cardiac engraftment of ex vivo expanded cells and explored means of enhancing cell-mediated repair of injured myocardium. [Expert Opin Biol Ther] Abstract Effect of Low-Level Laser-Treated Mesenchymal Stem Cells on Myocardial Infarction The authors evaluated the available experimental data on treatment of myocardial infarction using low-level laser. Eligible papers were characterized as in vivo experimental studies that evaluated the use of low-level laser therapy on stem cells in order to attenuate myocardial infarction. [Lasers Med Sci] Abstract Visit our reviews page to see a complete list of reviews in the muscle cell research field. | |
| |
SCIENCE NEWSSix-Month Results from Capricor’s HOPE-Duchenne Trial to Be Presented Capricor Therapeutics, Inc. will present interim six-month safety and efficacy results from its Phase I/II HOPE-Duchenne clinical trial of CAP-1002. [Press release from Capricor Therapeutics, Inc. discussing research presented at the 2017 Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference, Chicago] Press Release Biogen will present robust efficacy and safety data from Phase II and III SPINRAZA® studies. [Press release from Biogen discussing research to be presented at the Cure SMA 2017 Annual SMA Conference, Orlando] Press Release | |
| |
INDUSTRY NEWSCapricor Therapeutics, Inc. announced that Janssen Biotech, Inc. has decided not to exercise its option to exclusively license Capricor’s lead candidate CAP-1002 for development and commercialization in the field of cardiology. [Capricor Therapeutics, Inc.] Press Release Worldwide Clinical Trials Selected by BrainStorm as CRO for Phase III NurOwn Trial in ALS BrainStorm Cell Therapeutics Inc. announced that it has selected Worldwide Clinical Trials as its Clinical Research Organization for its planned Phase III study of NurOwn® in the treatment of amyotrophic lateral sclerosis. [BrainStorm Cell Therapeutics Inc.] Press Release | |
| |
POLICY NEWSTrump Administration Chooses Georgia Physician to Lead US Public-Health Agency Obstetrician and gynecologist Brenda Fitzgerald will direct the US Centers for Disease Control and Prevention, Secretary of Health and Human Services Tom Price announced. [Nature News] Editorial French Scientist Fined for Failure to Disclose Industry Ties In an unprecedented court case in Paris, an eminent French lung specialist has been fined €50,000 and given a six-month suspended jail sentence because he didn’t disclose his ties to the oil industry during a Senate air-pollution inquiry. [Nature News] Editorial
| |
EVENTSNEW 25th Biennial Congress of the European Association for Cancer Research (EACR) Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW PhD Position – Cardiac Tissue Engineering (Trinity College Dublin) Postdoctoral Research Scientist – Muscle Therapeutics (University of Oxford) Postdoctoral Research Scientist – Muscle Biology (University of Oxford) Postdoctoral Fellow – Cardiovascular Physiology (University of Nevada, Reno) Postdoctoral Fellow – Diabetes and Heart Disease (University Health Network) Postdoctoral Fellow – Physiology and Cell Biology (University of Nevada, Reno) Research Fellow – Cardiovascular Diseases (Mayo Clinic) Postdoctoral Position(s) – Skeletal Muscle Stem Cells (Inserm) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Muscle Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|